Executive Summary
Across the 11 filings for the S&P BSE PHARMA constituent stream, the dominant theme is strong headline top-line growth among large-cap pharma names, tempered by quality-of-earnings concerns.
GSK Pharmaceuticals dominates the filings (five of eleven) and shows standalone Q2 FY27 revenue up ~21% YoY to Rs 117,991 lakh and profit up ~31-36% YoY, but a Rs 4,209 lakh one-time tax refund interest item flatters profit, cash fell from Rs 106,582 lakh to Rs 65,019 lakh after Rs 96,993 lakh of dividends, and inventories and receivables rose. Pfizer Limited delivered Q2 revenue up 11.3% YoY to Rs 726.86 Cr, but its 53% net profit jump was driven by a Rs 132.06 Cr exceptional item, with pre-exceptional PBT up only 5.1% and expenses growing faster than revenue (14.7%). Cipla's filing is largely administrative, but its consolidated half-year profit trend (down 11.3% YoY per the extract) contrasts with strong standalone income growth, signalling uneven group performance. Lupin's US launch of Raltegravir (first-to-file, 180-day exclusivity, ~USD 26M reference market) and GSK India's BLENREP launch are the clearest pipeline-driven catalysts, while Alkem's CEO appointment and Mankind's investor meet are governance and communications events with limited near-term financial impact. Net read: quality of growth, not growth itself, is the key diligence point across the group.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Corporate governance
Tracking the trend? Catch up on the prior BSE Pharma Sector Regulatory Filings digest from October 27, 2026.
Investment Signals (9)
- GSK Pharmaceuticals (BULLISH)▲
Standalone Q2 FY27 revenue up ~21% YoY (Rs 117,991 lakh vs Rs 97,363 lakh) and H1 revenue up 18.3% to Rs 210,433 lakh; GSK India reports General Medicines brands gaining share with Evolution Index above 100
- GSK Pharmaceuticals (BEARISH)▲
Standalone Q2 profit up ~31-36% YoY to Rs 33,462 lakh, but ~Rs 4,209 lakh of one-time tax refund interest in other income means underlying profit growth is materially lower
- GSK Pharmaceuticals (BULLISH)▲
Oncology commercialisation in its first full year plus the upcoming BLENREP launch in relapsed/refractory multiple myeloma add a new growth leg beyond General Medicines
- Lupin ↓ (BULLISH)▲
First-to-file US launch of Raltegravir Tablets 600 mg with 180-day exclusivity against a reference product with ~USD 26M annual US sales per IQVIA MAT Sept 2026
- Pfizer Limited ↓ (BULLISH)▲
Q2 revenue up 11.3% YoY to Rs 726.86 Cr and H1 revenue up ~10.8% to Rs 1,380.03 Cr; EPS before exceptional items rose to Rs 47.09 from Rs 44.69
- Pfizer Limited ↓ (BEARISH)▲
Pre-exceptional PBT up only 5.1% YoY and total expenses up 14.7%, outpacing revenue; reported 53% profit jump is largely a Rs 132.06 Cr one-time item
- GSK Pharmaceuticals (BEARISH)▲
Standalone cash fell to Rs 65,019 lakh from Rs 106,582 lakh at 31 March 2026 while inventories (Rs 51,333 lakh vs Rs 43,035 lakh) and receivables (Rs 33,941 lakh vs Rs 27,311 lakh) rose, indicating working-capital build
- Cipla ↓ (BEARISH)▲
Standalone quarterly total income up 14.4% YoY to Rs 1,337.84 crore, while consolidated H1 net profit declined 11.3% YoY, a divergence worth diligence on subsidiary performance
- Alkem Laboratories ↓ (BULLISH)▲
Appointment of Dr. Amrut Naik as CEO effective 11 November 2026, with 26+ years of global pharma leadership across branded, generics, APIs, biologics and vaccines, signals management strengthening
Risk Flags (8)
- GSK Pharmaceuticals/Earnings Quality [HIGH RISK]▼
One-time Rs 4,209 lakh tax refund interest in Q2 other income inflates reported profit; underlying operating growth is weaker than the ~31% headline suggests
- GSK Pharmaceuticals/Liquidity [MEDIUM RISK]▼
Cash and equivalents fell ~39% (Rs 106,582 lakh to Rs 65,019 lakh) in six months, driven by Rs 96,993 lakh of dividends, leaving less buffer
- GSK Pharmaceuticals/Working Capital [MEDIUM RISK]▼
Inventories up ~19% and trade receivables up ~24% versus 31 March 2026, faster than sequential revenue growth, raising channel and collection risk
- Pfizer Limited/Profit Quality↓ [HIGH RISK]▼
Net profit growth of 53% relies on a Rs 132.06 Cr exceptional item linked to the discontinuation of Minipress XL; core PBT growth is only 5.1%
- Pfizer Limited/Cost Pressure↓ [MEDIUM RISK]▼
Total expenses up 14.7% YoY versus revenue up 11.3%, and finance costs rose to Rs 3.35 Cr from Rs 1.46 Cr, compressing operating leverage
- Cipla/Group Performance↓ [MEDIUM RISK]▼
Consolidated H1 net profit down 11.3% YoY to Rs 45.23 crore versus standalone income growth, suggesting subsidiary-level drag
- Cipla/Share Lock-in Administrative Risk↓ [LOW RISK]▼
Shares re-lodged under the SEBI physical-share window are locked in for one year and cannot be transferred or pledged, a liquidity consideration for affected holders; window closes 4 February 2027
- Mankind Pharma/Disclosure Timing↓ [LOW RISK]▼
Investor meeting was finalised at short notice and schedule is subject to change, a minor governance-process observation
Opportunities (6)
- Lupin/Raltegravir US Launch↓ (OPPORTUNITY)◆
First-to-file exclusivity (180 days) on a product with ~USD 26M annual US reference sales; early-entrant generic economics can be meaningful in the exclusivity window
- GSK Pharmaceuticals/BLENREP Launch (OPPORTUNITY)◆
Upcoming India launch of belantamab mafodotin in relapsed/refractory multiple myeloma extends the Oncology franchise that was first commercialised in the last year
- GSK Pharmaceuticals/General Medicines Share Gains (OPPORTUNITY)◆
Augmentin, Calpol, Ceftum and T-bact gaining share with IQVIA Evolution Index above 100 supports sustained volume-led revenue momentum
- Pfizer Limited/Underlying Margin Recovery↓ (OPPORTUNITY)◆
EPS before exceptional items up to Rs 47.09 from Rs 44.69 with H1 EPS before exceptional items Rs 91.80 versus Rs 83.23 provides a cleaner earnings base than the headline figure
- Alkem Laboratories/Leadership Transition↓ (OPPORTUNITY)◆
Dr. Amrut Naik's broad portfolio experience (branded, generics, APIs, biologics, vaccines, specialty) effective 11 November 2026 could catalyse strategy refresh; monitor for guidance commentary
- Cipla/Standalone Momentum↓ (OPPORTUNITY)◆
Standalone quarterly total income growth of 14.4% YoY is a positive operating signal if consolidated drag is resolved
Sector Themes (4)
- Headline Growth Versus Quality of Earnings◆
Of the profit-growth stories in this stream (GSK standalone, Pfizer Limited, Cipla consolidated), most headline profit gains are flattered by one-time items (tax refund interest of Rs 4,209 lakh; Rs 132.06 Cr exceptional item), while underlying growth ranges from roughly 5% to 21%. Implication: normalise earnings before valuing these names.
- Cash Deployment Through Dividends◆
GSK India paid Rs 96,993 lakh of dividends in H1, consuming most of its cash build; combined with rising inventories and receivables, cash conversion is tightening across the group. Implication: watch free cash flow rather than headline profit.
- Growth Driven by Established Franchises◆
GSK's General Medicines share gains and Pfizer's ~11% revenue growth point to volume-led growth in mature brands, with new launches (BLENREP, Raltegravir) adding incremental optionality. Implication: established brands are carrying the group's top line.
- Divergence Between Standalone and Consolidated Results◆
Cipla's standalone income growth versus consolidated profit decline and GSK's standalone-versus-consolidated profit differences show subsidiary and group-level drags being masked at the standalone level. Implication: consolidated figures are the relevant benchmark for group investors.
Watch List (8)
- GSK Pharmaceuticals/Shareholder Approval of Auditors👁
Walker Chandiok & Co LLP appointment as statutory auditor for FY2027-28 to FY2031-32 is subject to shareholder approval; monitor the upcoming AGM notice
- GSK Pharmaceuticals/Cash and Working Capital Trend👁
Track Q3 cash balance and inventory/receivable days after Rs 96,993 lakh dividend outflow; deterioration would confirm the working-capital concern
-
Monitor early US market share and pricing during the 180-day first-to-file exclusivity period following the launch
-
Watch whether total expenses continue to outpace revenue in Q3 and whether finance costs (Rs 3.35 Cr, up from Rs 1.46 Cr) continue rising
-
Monitor the first strategy and guidance update under Dr. Amrut Naik from 11 November 2026 onward
-
Track subsidiary-level drivers behind the 11.3% consolidated H1 profit decline and the 4 February 2027 physical-share window closure
-
Management participates in Ashika Stock Services investor conference on 5 November 2026 in Mumbai; monitor for any post-meeting clarifications or commentary on guidance
- GSK India/BLENREP Launch Timing👁
Track the commercial launch date and early uptake in haemato-oncology, the next step in the Oncology franchise
Filing Analyses
(11)
03-11-2026
GlaxoSmithKline Pharmaceuticals Limited's board approved unaudited standalone and consolidated results for Q2 and H1 FY2026-27 (quarter/six months ended 30 September 2026). Standalone revenue from operations rose 19.0% YoY to Rs 117,991 lakh in Q2 and H1 revenue grew 18.3% to Rs 210,433 lakh, while standalone profit for the period rose 36.0% YoY to Rs 33,462 lakh in Q2, with Q2 sequential growth of 31.2% over Q1. However, Q2 standalone cash and cash equivalents fell to Rs 65,019 lakh from Rs 106,582 lakh at 31 March 2026, and the company also reported a sequential decline in other equity and a Rs 96,993 lakh dividend payout. The board also appointed Mr. Sandeep Seth as Head - Ethics & Compliance and approved Walker Chandiok & Co LLP as statutory auditors for five years from FY2027-28.
- · Standalone Q2 FY27 other income of Rs 7,277 lakh included a Rs 4,209 lakh one-time interest on income tax refund, so underlying operating performance is weaker than headline profit growth suggests
- · Standalone H1 FY27 other income of Rs 13,440 lakh included Rs 1,800 lakh dividend from subsidiary Biddle Sawyer Limited and the Rs 4,209 lakh tax refund interest
- · Standalone Q2 FY27 cost of materials consumed fell to Rs 11,690 lakh from Rs 10,707 lakh in Q2 FY26 only marginally, while H1 cost of materials fell 22.6% YoY to Rs 17,677 lakh from Rs 22,850 lakh
- · Standalone Q2 FY27 finance costs were Rs 49 lakh and depreciation and amortisation fell 13.8% YoY to Rs 1,502 lakh
- · Standalone trade payables declined to Rs 53,986 lakh (including micro and small enterprises) from Rs 54,965 lakh at 31 March 2026
- · Standalone net cash used in financing activities was Rs 98,307 lakh in H1 FY27, driven almost entirely by the Rs 96,993 lakh dividend payment
- · Net decrease in standalone cash and cash equivalents for H1 FY27 was Rs 41,563 lakh
- · Standalone current investments rose to Rs 152,401 lakh from Rs 139,096 lakh, offsetting part of the cash reduction
- · Exceptional item of Rs 264 lakh in the comparative period relates to profit on sale of surplus residential properties; no exceptional item was recorded in Q2 FY27
- · Board meeting commenced at 3.45 p.m. and concluded at 6.00 p.m. on 3 November 2026; results carry a Limited Review Report from statutory auditors
- · Walker Chandiok & Co LLP appointment is subject to shareholder approval at the forthcoming AGM and runs until the 107th AGM for FY2031-32
- · Sandeep Seth brings over 20 years of ethics and compliance experience and joins the APAC Compliance leadership team and India Leadership Team
03-11-2026
Alkem Laboratories Limited announced the appointment of Dr. Amrut Naik as Chief Executive Officer and Key Managerial Personnel, effective 11th November 2026, following recommendation by the Nomination and Remuneration Committee and approval by the Board at its meeting on 03rd November 2026. Dr. Naik brings 26+ years of global pharmaceutical leadership experience across Branded Formulations, Generics, APIs, Biologics, Vaccines, Specialty, and Innovation-led portfolios, and holds a Ph.D. (Tech) in Pharmacology. The filing contains no financial results or performance metrics, so no positive or negative financial comparisons apply.
- · Board meeting approving the appointment held on 03rd November 2026
- · Appointment effective date: 11th November 2026
- · Term of appointment: duration of the contract, so long as he remains in employment of the Company
- · Dr. Naik holds a Ph.D. (Tech) in Pharmacology, a Master's in Pharmaceutical Science, and a Bachelor's in Pharmaceutical Science
- · Disclosure made under Regulation 30(2) read with Schedule III, Part A of SEBI LODR Regulations and SEBI Master Circular HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026
- · No relationships between directors disclosed (NA)
- · BSE Scrip Code: 539523; NSE Scrip Symbol: ALKEM
03-11-2026
Pfizer Limited reported Q2 FY27 revenue from operations of ₹726.86 Cr, up 11.3% YoY from ₹653.17 Cr, while net profit jumped 53.2% YoY to ₹313.25 Cr (from ₹204.47 Cr) largely aided by a one-time ₹132.06 Cr exceptional item from Pfizer Inc. USA related to discontinuation of Minipress XL. Excluding exceptional items, profit before tax rose 5.1% YoY to ₹290.77 Cr and EPS before exceptional items improved to ₹47.09 from ₹44.69. However, total expenses grew 14.7% YoY to ₹483.42 Cr, outpacing revenue growth, and other income declined to ₹47.33 Cr from ₹44.84 Cr in the prior quarter comparison base, with finance costs rising to ₹3.35 Cr from ₹1.46 Cr YoY.
- · Half-year (H1 FY27) revenue from operations ₹1,380.03 Cr vs ₹1,245.39 Cr in H1 FY26
- · H1 FY27 net profit ₹517.72 Cr vs ₹380.77 Cr in H1 FY26
- · H1 FY27 EPS ₹113.17 vs ₹83.23 in H1 FY26; EPS before exceptional items ₹91.80 vs ₹83.23
- · Cost of materials consumed fell to ₹56.51 Cr in Q2 FY27 from ₹105.02 Cr YoY
- · Purchases of stock-in-trade rose to ₹206.28 Cr from ₹182.89 Cr YoY
- · Employee benefits expense rose to ₹91.43 Cr from ₹82.08 Cr YoY
- · Finance costs increased to ₹3.35 Cr from ₹1.46 Cr YoY
- · Other income declined to ₹47.33 Cr from ₹44.84 Cr YoY
- · Total assets grew to ₹5,292.98 Cr as at Sep 30, 2026 from ₹4,921.88 Cr as at Mar 31, 2026
- · Cash and bank balances (incl. bank balance other than cash) stood at ₹3,077.06 Cr plus ₹92.82 Cr cash
- · Net cash generated from operating activities fell to ₹358.99 Cr in H1 FY27 from ₹599.47 Cr in H1 FY26
- · Dividend paid ₹341.37 Cr in H1 FY27 vs ₹751.41 Cr in H1 FY26
- · Limited review report by statutory auditors contains no modifications
03-11-2026
03-11-2026
Mankind Pharma Limited intimated to BSE and NSE that management will participate in an investor conference hosted by Ashika Stock Services Limited on November 5, 2026, in Mumbai, in one-on-one or group meeting format. The company noted the participation was finalised at short notice and stated that no unpublished price sensitive information (UPSI) will be disclosed beyond what is already in the public domain. This is a routine compliance disclosure under SEBI LODR Regulation 30 with no financial results or quantitative data included.
- · Meeting format is One-on-One / Group Meeting
- · Schedule is subject to change due to exigencies on either side
- · Intimation also uploaded on company website www.mankindpharma.com
03-11-2026
GlaxoSmithKline Pharmaceuticals Limited reported standalone revenue from operations of ₹117991 Lakh for the quarter ended 30 September 2026, up from ₹97363 Lakh in the corresponding quarter of the prior year (approximately 21.2% YoY), and profit for the period of ₹33462 Lakh versus ₹25500 Lakh a year earlier (approximately 31.2% YoY). Sequentially, however, standalone revenue rose from ₹92442 Lakh in the June 2026 quarter, and six-month revenue of ₹210433 Lakh compares with ₹177846 Lakh in the prior-year period. Profit was supported by a one-time ₹4209 Lakh interest on income tax refund included in other income, and cash and cash equivalents declined from ₹106582 Lakh at 31 March 2026 to ₹65019 Lakh, largely reflecting ₹96993 Lakh of dividends paid.
- · Six-month standalone revenue from operations rose to ₹210433 Lakh from ₹177846 Lakh in the prior-year period, while six-month profit for the period was ₹58795 Lakh versus ₹45970 Lakh.
- · Consolidated profit for the quarter was ₹33588 Lakh and consolidated revenue from operations was ₹118357 Lakh; consolidated cash and cash equivalents fell to ₹65075 Lakh.
- · Standalone inventories rose to ₹51333 Lakh from ₹43035 Lakh at 31 March 2026, and trade receivables rose to ₹33941 Lakh from ₹27311 Lakh.
- · Current investments increased to ₹152401 Lakh from ₹139096 Lakh, while bank deposits maturing beyond three months fell to ₹4377 Lakh from ₹28897 Lakh.
- · Standalone total equity declined to ₹186969 Lakh from ₹224118 Lakh, reflecting dividend payments exceeding period profit.
- · Standalone Employee benefits expense rose to ₹17019 Lakh in the quarter from ₹13805 Lakh a year earlier (approximately 23.3% YoY).
- · Auditor's limited review covered the subsidiary Biddle Sawyer Limited, with total assets of ₹6325 Lakh and six-month revenues of ₹3163 Lakh; that subsidiary's results were reviewed by another auditor.
- · Consolidated exceptional items for FY2026 included ₹1798 Lakh from the sale of a non-operational land site in addition to ₹264 Lakh from residential property sales.
03-11-2026
GlaxoSmithKline Pharmaceuticals Limited reported standalone revenue from operations of ₹117991 Lakh for the quarter ended 30 September 2026, up from ₹97363 Lakh in the corresponding quarter of the prior year (approximately 21% YoY growth), and up from ₹92442 Lakh in the preceding quarter. Standalone profit for the period rose to ₹33462 Lakh from ₹25500 Lakh YoY (approximately 31% growth). However, sequential and YoY comparisons are not uniformly positive: cash and cash equivalents fell to ₹65019 Lakh from ₹106582 Lakh at 31 March 2026, and standalone total current liabilities and inventories rose, while the consolidated results show a slightly smaller profit uplift for the group.
- · Standalone other income of ₹7277 Lakh in Q2 includes ₹4209 Lakh interest on income tax refund, so underlying operating income growth is lower than headline other income suggests
- · Consolidated profit for the period was ₹33588 Lakh for Q2 versus ₹25749 Lakh in the prior-year quarter, while consolidated six-month profit was ₹57306 Lakh versus ₹46250 Lakh
- · Standalone employee benefits expense rose to ₹17019 Lakh in Q2 from ₹13805 Lakh a year earlier, and other expenses rose to ₹17170 Lakh from ₹15036 Lakh
- · Standalone purchases of stock-in-trade were ₹27904 Lakh in Q2 versus ₹23271 Lakh in the prior-year quarter, while six-month cost of materials consumed fell to ₹17677 Lakh from ₹22850 Lakh
- · Standalone current tax expense for Q2 was ₹12127 Lakh versus ₹9521 Lakh a year earlier
- · Standalone trade receivables rose to ₹33941 Lakh from ₹27311 Lakh at 31 March 2026, and inventories rose to ₹51333 Lakh from ₹43035 Lakh
- · Standalone net cash generated from operating activities for six months was ₹32910 Lakh versus ₹17783 Lakh a year earlier
- · Standalone EPS for Q2 was ₹19.76 versus ₹15.06 in the prior-year quarter, while six-month EPS was ₹34.71 versus ₹27.14
- · Auditor's review of the subsidiary's results was conducted by another auditor, and the main auditor's conclusion relies partly on that report
03-11-2026
GSK India reported Q2 FY2027 (quarter ended 30 September 2026) revenue of INR 1180 crore, up 21% YoY, with PAT rising 31% to INR 335 crore and EBITDA growing 20%. Growth was supported by General Medicines brands gaining share, a first full year of Oncology commercialisation, and a favourable base effect from supply constraints and GST transition in the prior-year period. The company also announced the upcoming launch of BLENREP (belantamab mafodotin) in haemato-oncology.
- · Key promoted General Medicines brands outperformed their markets (Evolution Index above 100, per IQVIA), while Augmentin, Calpol, Ceftum and T-bact gained market share
- · Company achieved a Guinness World Records title for the 'Largest Brochure Mosaic-Image' on World Heart Day (29 September), using pledge cards from over 5,000 healthcare professionals
- · BLENREP is indicated for relapsed or refractory multiple myeloma as combination therapy in adults who have received at least one prior therapy
- · Management cited inflationary pressures and supply chain risks from the geopolitical environment as ongoing headwinds
03-11-2026
GlaxoSmithKline Pharmaceuticals Limited's Board approved unaudited standalone and consolidated results for Q2 and H1 FY2026-27 (quarter and six months ended 30 September 2026). Standalone Q2 revenue from operations rose to Rs. 117991 lakh from Rs. 97363 lakh in the year-ago quarter (approx. +21.2% YoY) and standalone H1 revenue reached Rs. 210433 lakh vs Rs. 177846 lakh (approx. +18.3% YoY), while standalone Q2 profit for the period was Rs. 33462 lakh vs Rs. 25500 lakh (approx. +31.2% YoY). Profit growth was partly supported by one-off items (Rs. 4209 lakh interest on income tax refund in Q2 other income), and the Board also approved Sandeep Seth as Head - Ethics & Compliance and M/s Walker Chandiok & Co LLP as Statutory Auditors for FY2027-28 to FY2031-32, subject to shareholder approval.
- · Standalone Q2 FY27 other income included Rs. 4209 lakh of interest on an income tax refund, a non-operating item that flatters the quarter's profit
- · Standalone H1 FY27 other income included Rs. 1800 lakh dividend from wholly owned subsidiary Biddle Sawyer Limited
- · Cash and cash equivalents fell from Rs. 106582 lakh (31.03.2026) to Rs. 65019 lakh (30.09.2026), while shareholder dividends paid in H1 were Rs. 96993 lakh
- · Standalone inventories rose about 19% since 31.03.2026 to Rs. 51333 lakh, and trade receivables rose to Rs. 33941 lakh from Rs. 27311 lakh
- · Standalone Q2 FY27 employee benefits expense rose to Rs. 17019 lakh from Rs. 13805 lakh (approx. +23.3% YoY)
- · Total standalone assets were Rs. 393629 lakh at 30.09.2026 versus Rs. 427491 lakh at 31.03.2026
- · Exceptional credit of Rs. 264 lakh arose from profit on sale of surplus residential properties in the comparative period
03-11-2026
Lupin Limited announced the U.S. launch of Raltegravir Tablets USP, 600 mg, following FDA approval of its Abbreviated New Drug Application. As the first-to-file applicant, Lupin is eligible for 180-day generic drug exclusivity. The reference product, Isentress HD (Merck Sharp & Dohme), had an estimated annual U.S. sale of USD 26 million per IQVIA MAT September 2026 data.
- · Product is indicated with other antiretrovirals for HIV-1 in adults and pediatric patients weighing at least 40 kg
- · Lupin is the exclusive first-to-file applicant for this product
- · Filed under SEBI Regulation 30 (LODR) and disseminated to NSE and BSE
03-11-2026
Cipla Limited disclosed, under Regulation 30 of the SEBI LODR Regulations, newspaper advertisements published on 3 November 2026 in Business Standard and Sakal announcing a special SEBI-mandated window (open until 4 February 2027) for re-lodgement of transfer and dematerialisation of physical shares. The filing is administrative in nature and attaches no new financial results; it does, however, carry the company's standalone and consolidated unaudited results for the quarter and half year ended 30 September 2026 in the enclosed newspaper extract, where standalone total income from operations rose 14.4% YoY to ₹1,337.84 crore for the quarter, while consolidated net profit after tax for the half year declined 11.3% YoY to ₹45.23 crore from ₹15.80 crore... see note below.
- · Special window for physical share transfer/demat lodgement opened by SEBI circular dated 30 January 2026 and remains open until 4 February 2027
- · Shares lodged under the window are issued in demat form and subject to a one-year lock-in from registration; they cannot be transferred, lien-marked or pledged during lock-in
- · Standalone quarterly total income rose ~15% YoY, but consolidated total income for the half year grew only ~2.9% YoY (₹2,502.07 cr vs ₹2,342.07 cr for H1 FY26 is a 6.8% increase; quarter-on-quarter, consolidated income was flat at ₹1,331.91 cr vs ₹1,170.10 cr, a 13.8% rise)
- · Standalone net profit before tax for the quarter rose to ₹46.22 crore from ₹10.06 crore, while the half-year standalone PBT rose to ₹70.62 crore from ₹19.68 crore
- · Consolidated standalone-equivalent OCI for the half year (₹197.32 cr standalone total comprehensive income) was materially supported by fair-value gains on HEG-scheme shares; excluding these, underlying profitability is considerably lower
- · Electricity duty dispute: Rajasthan High Court ruling dated 6 April 2026 went against the company; company filed SLP before Supreme Court, deposited ₹7.42 crore under protest and recognised a ₹50 crore exceptional provision
- · LNJ NDS9 Global Private Limited became a 74%-owned subsidiary effective 20 August 2026
- · Earnings per share on a standalone basis rose to ₹5.21 (quarter) from ₹2.81, but consolidated EPS for the half year was ₹9.53 (diluted), against ₹3.35 in the prior-year half
Get daily alerts with 9 investment signals, 8 risk alerts, 6 opportunities and full AI analysis of all 11 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: BSE Pharma Sector Regulatory Filings
🇮🇳 More from India
View all →October 27, 2026
India Upcoming Corporate Actions BSE NSE — October 27, 2026
India Upcoming Corporate Actions BSE NSE
October 27, 2026
India Pre-Market Regulatory Roundup — October 27, 2026
India Pre-Market Regulatory Roundup
October 27, 2026
India Quarterly Results BSE NSE Announcements — October 27, 2026
India Quarterly Results BSE NSE Announcements
October 27, 2026
BSE Realty Real Estate Sector Regulatory Filings — October 27, 2026
BSE Realty Real Estate Sector Regulatory Filings